SCHEMBL22423960

SCHEMBL22423960

CNC(=O)c1ccc(-n2c(NCc3ccc(OC)cc3)nc3c(c2=O)CCN(C(=O)c2ccc(Cl)c(Cl)c2)C3)cc1

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ PRLHR P49683 7/20 0.48
▸ HDAC6 Q9UBN7 1/20 0.41
▸ MAPT P10636 3/20 0.40
▸ LMNA P02545 2/20 0.40
▸ KMT2A Q03164 2/20 0.40
▸ MEN1 O00255 1/20 0.40
▸ ALDH1A1 P00352 1/20 0.40
▸ GRM5 P41594 1/20 0.39
▸ RPA1 P27694 2/20 0.39
▸ TP53 P04637 1/20 0.38
▸ POLB P06746 1/20 0.38
▸ SMN1; SMN2 Q16637 1/20 0.38
▸ HTR1A P08908 1/20 0.37
▸ SSTR3 P32745 1/20 0.37
▸ PDE5A O76074 1/20 0.37
▸ MAPK14 Q16539 1/20 0.37
▸ ADAMTS4 O75173 1/20 0.36
▸ HPGD P15428 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22410896 0.92 PRLHR (0.49) PRLHRHDAC6MAPTLMNAKMT2A
SCHEMBL22424700 0.91 PRLHR (0.48) PRLHRHDAC6MAPTLMNAKMT2A
SCHEMBL22424701 0.90 PRLHR (0.47) PRLHRHDAC6MAPTLMNAKMT2A
SCHEMBL22410768 0.90 PRLHR (0.47) PRLHRHDAC6MAPTLMNAKMT2A
SCHEMBL22424690 0.90 PRLHR (0.49) PRLHRHDAC6MAPTLMNAKMT2A
SCHEMBL22424283 0.87 PRLHR (0.50) PRLHRHDAC6MAPTLMNAKMT2A
SCHEMBL22424572 0.87 PRLHR (0.47) PRLHRMAPTLMNAKMT2AMEN1
SCHEMBL22424388 0.87 PRLHR (0.47) PRLHRHDAC6MAPTLMNAKMT2A
SCHEMBL22424229 0.86 PRLHR (0.52) PRLHRHDAC6GRM5HTR1A
SCHEMBL22424695 0.86 PRLHR (0.53) PRLHRHDAC6MAPTLMNAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020182990-A1 FUSED RING PYRIMIDONE DERIVATIVES FOR USE IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES Janssen Sciences Ireland Unlimited Company (IE) 2020-09-17 — — WO disclosed
Send feedback